Featured Research

from universities, journals, and other organizations

Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers

Date:
October 21, 2003
Source:
Stanford University Medical Center
Summary:
An old drug may have found a new role treating an incurable form of brain cancer called glioblastoma, according to preliminary research at Stanford University School of Medicine. The drug, called arsenic trioxide, increases the effectiveness of radiation therapy in mice with the disease.

STANFORD, Calif. - An old drug may have found a new role treating an incurable form of brain cancer called glioblastoma, according to preliminary research at Stanford University School of Medicine. The drug, called arsenic trioxide, increases the effectiveness of radiation therapy in mice with the disease. The researchers will present their work Oct. 22 at the American Society for Therapeutic Radiology and Oncology.

Related Articles


"Many brain cancers are incurable," said Susan Knox, MD, PhD, associate professor of radiation oncology, who led the study. "The use of arsenic trioxide with radiation may be one way to make the treatment more effective."

Arsenic trioxide has been approved by the U.S. Food and Drug Administration for use in treating a rare form of leukemia. It works in part by releasing damaging molecules called reactive oxygen species, or ROS, that destroy cancer cells. Shoucheng Ning, MD, PhD, a research associate working with Knox, thought the drug would release even higher levels of ROS when coupled with radiation therapy.

The team tested this idea in both the lab dish and in mice. In both cases, exposing glioblastoma cells to radiation within two hours of receiving a dose of arsenic trioxide amplified the effects of radiation treatment on its own.

The mice in this study had tumors formed by injecting human glioblastoma cells under the skin. In these mice, arsenic trioxide alone did not slow the tumor growth, and radiation alone delayed the tumor's growth for only 45 days. The combined treatment eliminated the tumor in four out of five mice and shrunk the tumor by 90 percent in the fifth mouse. The tumors had not begun growing again when the trial ended three months later.

Ning said that the arsenic trioxide dose the mice received is low enough that it would not be toxic in humans. "The concentration we used is already known to be achievable and is well tolerated in humans," he said.

"Based on these results we think the data are compelling enough to move forward with human trials," Knox said. She hopes to start preliminary human trials in conjunction with Iris Gibbs, MD, assistant professor of radiation oncology, by next year. The initial trials will be in recurrent glioblastoma and pediatric brain stem glioma, though Knox hopes to test the therapy in other cancers in the future.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers." ScienceDaily. ScienceDaily, 21 October 2003. <www.sciencedaily.com/releases/2003/10/031021061411.htm>.
Stanford University Medical Center. (2003, October 21). Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2003/10/031021061411.htm
Stanford University Medical Center. "Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers." ScienceDaily. www.sciencedaily.com/releases/2003/10/031021061411.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins